Novo Nordisk’s Oral Wegovy Pill Nets 18,000 Prescriptions, Catalent Integration to Double U.S. Supply
Novo Nordisk launched the FDA-approved oral Wegovy pill in January 2026, achieving over 18,000 prescriptions in its debut week and 8,000 fills by the second week. Catalent fill-finish integration will double U.S. supply capacity by mid-2026 and support margin expansion.
1. 2025 Underperformance and 2026 Rebound
Novo Nordisk shares fell by roughly 40% in 2025 as competitive pressures from generic competitors and rival GLP-1 therapies weighed on growth and investor sentiment. In the first weeks of 2026, however, the stock has recovered approximately 22% year-to-date, driven by renewed optimism around the company’s obesity franchise and cost-saving initiatives. This swing reflects a restoration of investor confidence after a leadership change in mid-2025 and a clear strategic shift toward novel delivery formats and pipeline expansion.
2. Oral Wegovy Pill Launch and Market Expansion
In January 2026, Novo Nordisk secured FDA approval for an oral formulation of Wegovy, marking the first once-daily GLP-1 obesity therapy in pill form. The product recorded over 18,000 prescriptions in its debut week, extending reach beyond traditional injectable patients. Management estimates that this innovation expands the addressable U.S. market to roughly 85 million adults with overweight or obesity, up from 40 million previously, and expects prescription volumes to accelerate in the coming quarters as primary-care adoption grows.
3. Supply Chain Integration and Cost-Saving Measures
Restructuring costs were front-loaded in the third quarter, enabling DKK 1 billion of additional savings to flow through Q4 earnings. Novo Nordisk’s integration of Catalent’s fill-finish facility is on track to double U.S. supply-chain capacity by mid-2026, alleviating prior bottlenecks. These operational enhancements are forecast to support gross-margin expansion of 200–300 basis points over the next 12 months and reduce time-to-market for new presentations of established therapies.
4. Pipeline Catalysts and Label Expansions
Beyond Wegovy, Novo Nordisk is preparing for the launch of CagriSema, a next-generation combination GLP-1/glucagon analog, with pivotal data expected in late 2026. The company has also received label expansions for chronic kidney disease and heart-failure indications for its Type 2 diabetes portfolio, potentially unlocking an additional 10 million patients globally. These developments position Novo Nordisk to sustain double-digit revenue growth through 2027, according to consensus estimates.